| Product Code: ETC7635578 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Ireland`s import shipments of non-alcoholic steatohepatitis (NASH) biomarkers in 2024 continued to be dominated by key exporters such as the USA, UK, Germany, Metropolitan France, and Serbia. Despite a challenging market environment, the high Herfindahl-Hirschman Index (HHI) indicates a concentrated market. The compound annual growth rate (CAGR) from 2020 to 2024 was -4.18%, reflecting a declining trend. Furthermore, the significant growth rate decline of -30.16% from 2023 to 2024 suggests a notable contraction in the market for NASH biomarkers in Ireland.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Overview |
3.1 Ireland Country Macro Economic Indicators |
3.2 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, 2021 & 2031F |
3.3 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Industry Life Cycle |
3.4 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Porter's Five Forces |
3.5 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume Share, By Biomarker Type, 2021 & 2031F |
3.6 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of non-alcoholic steatohepatitis (NASH) in Ireland |
4.2.2 Growing awareness about the importance of early detection and diagnosis of NASH |
4.2.3 Technological advancements in biomarker development for NASH |
4.3 Market Restraints |
4.3.1 High cost associated with biomarker testing and diagnosis |
4.3.2 Limited reimbursement policies for NASH biomarker testing |
4.3.3 Lack of standardized guidelines for the use of biomarkers in NASH diagnosis and management |
5 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Trends |
6 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, By Types |
6.1 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, By Biomarker Type |
6.1.1 Overview and Analysis |
6.1.2 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Biomarker Type, 2021- 2031F |
6.1.3 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Serum Biomarkers, 2021- 2031F |
6.1.4 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Biomarker Panels, 2021- 2031F |
6.1.5 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Fibrosis Biomarkers, 2021- 2031F |
6.1.6 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Imaging Biomarkers, 2021- 2031F |
6.1.7 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, By End User |
6.2.1 Overview and Analysis |
6.2.2 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.2.3 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Diagnostic Centers, 2021- 2031F |
6.2.4 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Others, 2021- 2031F |
7 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Import-Export Trade Statistics |
7.1 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Export to Major Countries |
7.2 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Imports from Major Countries |
8 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Key Performance Indicators |
8.1 Number of research studies focusing on NASH biomarkers in Ireland |
8.2 Adoption rate of NASH biomarker testing by healthcare providers |
8.3 Investment in RD for new biomarkers specific to the Irish population |
9 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Opportunity Assessment |
9.1 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Opportunity Assessment, By Biomarker Type, 2021 & 2031F |
9.2 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Competitive Landscape |
10.1 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue Share, By Companies, 2024 |
10.2 Ireland Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |